In vitro characterization and clinical use of platelet‐rich plasma‐derived Endoret‐Gel as an autologous treatment for atrophic scars

• DOI: 10.1111/jocd.13212
• Publication Date: 2019-11-11T09:20:17Z
• Authors: Cristina García; Ander Pino; Natalia Jimenez; MªTeresa Truchuelo; Pedro Jaén; Eduardo Anitua
• Keywords: Platelet-rich fibrin

Abstract Background Normal healing process becomes severely dysregulated in pathophysiological conditions such as inflammation, infection or underlaying diseases. These scenarios hamper the standard pattern and dermal fibrotic tissue develops. Objective In present study a novel three‐dimensional formulation (Endoret‐Gel) based on plasma rich growth factors technology (Endoret‐PRGF) has been assessed for atrophic scar management. Materials methods Microstructure analysis, factor content, projection capacity of both formulations (Endoret‐Gel Endoret‐PRGF) was assessed. Additionally, clinical evaluation Endoret‐Gel treatment also performed case an extense scar. Results presented high molecular weight plasmatic proteins that formed solid thermal aggregates enclosed by stable fibrin network. This higher cutaneous compared with Endoret‐PRGF. Both load bioactive EGF, PDGF‐AB, IGF‐I being liquid Clinical results evidenced infiltrations derived early volumetric disposal maintained several months. The provided immediate soft augmentation amelioration effect translated into noticeable improvement injury. No side effects adverse events were reported during ten‐month follow‐up period. Conclusion preliminary findings suggest may act not only temporary volumizer but stimulator might be used monotherapy